ProBac__A_consortium_to_pioneer_the_development_of_PROtein__BACteriocins_as_therapeutic_antibiotics_-sc-4526
ProBac__A_consortium_to_pioneer_the_development_of_PROtein__BACteriocins_as_therapeutic_antibiotics_
Through the development of the use of protein antibiotics against multi-drug resistant, hospital-acquired Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae) and with a view to personalised medicine (design/select protein antibiotics based on pathogen genome data), the study aims after 5 years to have a panel of diagnostic reagents for more extensive animal tests and phase I clinical trials (translation award application). The mechanisms of acquisition and resistance will be identified using TraDIS RNAseq and genome sequencing. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
Through the development of the use of protein antibiotics against multi-drug resistant, hospital-acquired Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae) and with a view to personalised medicine (design/select protein antibiotics based on pathogen genome data), the study aims after 5 years to have a panel of diagnostic reagents for more extensive animal tests and phase I clinical trials (translation award application). The mechanisms of acquisition and resistance will be identified using TraDIS RNAseq and genome sequencing. http://www.sanger.ac.uk/resources/downloads/bacteria/